345 related articles for article (PubMed ID: 19729658)
1. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.
Fine B; Hodakoski C; Koujak S; Su T; Saal LH; Maurer M; Hopkins B; Keniry M; Sulis ML; Mense S; Hibshoosh H; Parsons R
Science; 2009 Sep; 325(5945):1261-5. PubMed ID: 19729658
[TBL] [Abstract][Full Text] [Related]
2. P-REX2a driving tumorigenesis by PTEN inhibition.
Leslie NR
Sci Signal; 2009 Oct; 2(94):pe68. PubMed ID: 19861688
[TBL] [Abstract][Full Text] [Related]
3. MiR-637 suppresses melanoma progression through directly targeting P-REX2a and inhibiting PTEN/AKT signaling pathway.
Zhang J; Liu WL; Zhang L; Ge R; He F; Gao TY; Tian Q; Mu X; Chen LH; Chen W; Li X
Cell Mol Biol (Noisy-le-grand); 2018 Aug; 64(11):50-57. PubMed ID: 30213289
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC.
Liao Z; Zheng Q; Wei T; Zhang Y; Ma J; Zhao Z; Sun H; Nan K
Oncol Res; 2020 Mar; 28(2):147-159. PubMed ID: 31711559
[TBL] [Abstract][Full Text] [Related]
5. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
6. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a.
Guo B; Liu L; Yao J; Ma R; Chang D; Li Z; Song T; Huang C
Mol Cancer Res; 2014 Mar; 12(3):313-21. PubMed ID: 24375644
[TBL] [Abstract][Full Text] [Related]
7. Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin.
Ai Y; Zhou Q; Li L; Pan Z; Guo M; Han J
Oncol Lett; 2018 Mar; 15(3):3185-3191. PubMed ID: 29435055
[TBL] [Abstract][Full Text] [Related]
8. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway.
Wang F; Li L; Chen Z; Zhu M; Gu Y
Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965
[TBL] [Abstract][Full Text] [Related]
10. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
Jang K; Kim M; Seo HS; Shin I
Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
[TBL] [Abstract][Full Text] [Related]
11. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
13. Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling.
Foster JS; Fish LM; Phipps JE; Bruker CT; Lewis JM; Bell JL; Solomon A; Kestler DP
BMC Cancer; 2013 May; 13():227. PubMed ID: 23648148
[TBL] [Abstract][Full Text] [Related]
14. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
[TBL] [Abstract][Full Text] [Related]
15. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.
Ma J; Sawai H; Ochi N; Matsuo Y; Xu D; Yasuda A; Takahashi H; Wakasugi T; Takeyama H
Mol Cell Biochem; 2009 Nov; 331(1-2):161-71. PubMed ID: 19437103
[TBL] [Abstract][Full Text] [Related]
16. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
17. MADD is a downstream target of PTEN in triggering apoptosis.
Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS
J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283
[TBL] [Abstract][Full Text] [Related]
18. Methylation and mutation of the inhibin‑α gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
Ko H; Ahn HJ; Kim YI
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958114
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor α induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.
Noh EM; Lee YR; Chay KO; Chung EY; Jung SH; Kim JS; Youn HJ
Mol Med Rep; 2011; 4(2):215-9. PubMed ID: 21468554
[TBL] [Abstract][Full Text] [Related]
20. Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis.
Hodakoski C; Hopkins BD; Barrows D; Mense SM; Keniry M; Anderson KE; Kern PA; Hawkins PT; Stephens LR; Parsons R
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):155-60. PubMed ID: 24367090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
